Sinotherapeutics, Inc. Class A

As of June 30, 2026, Sinotherapeutics, Inc. Class A carries a market capitalization of 3.41B, placing it among publicly traded companies globally. Its enterprise value stands at 2.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sinotherapeutics, Inc. Class A has 453.34M shares outstanding.

As of June 30, 2026, Sinotherapeutics, Inc. Class A trades at a trailing price-to-earnings ratio of 85.29. The price-to-sales ratio is 7.94, and the price-to-book ratio stands at 2.58.

As of June 30, 2026, Sinotherapeutics, Inc. Class A trades at an EV/EBITDA multiple of 59.55 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 59.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.60B versus a market cap of 3.41B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sinotherapeutics, Inc. Class A maintains a current ratio of 10.19, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.00, indicating conservative leverage, while an interest coverage ratio of 33,489.68 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sinotherapeutics, Inc. Class A posted a return on equity (ROE) of 2.97, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.94 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.64, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.97, useful for judging operating efficiency across full business cycles. The company generates approximately 1.31M in revenue per employee across its workforce of 317.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.79 indicates how many times Sinotherapeutics, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sinotherapeutics, Inc. Class A recorded 5.10M in income tax expense. That works out to an effective tax rate of 11.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 43.92M, leaving 38.82M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sinotherapeutics, Inc. Class A's stock has declined approximately 22.63% over the past 52 weeks. The 50-day moving average sits at 9.44, while the 200-day moving average is 9.35.

Over the twelve months ended June 30, 2026, Sinotherapeutics, Inc. Class A generated 416.94M in revenue and converted that into 38.82M in net income, yielding earnings per share of 0.09. EBITDA reached 43.58M, while operating income came in at 48.55M.

As of June 30, 2026, Sinotherapeutics, Inc. Class A holds 813.72M in cash and equivalents against 38,187.26 in total debt, resulting in a net debt position of -155.40M. Total book value stands at 1.32B, with working capital of 881.97M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sinotherapeutics, Inc. Class A posted a gross margin of 40.10, reflecting its pricing power and cost economics. The operating margin of 11.64 and net profit margin of 9.31 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Sinotherapeutics, Inc. Class A paid dividends of 0.02 per share. The dividend payout ratio of 24.38 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.00, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sinotherapeutics, Inc. Class A shareholders.

As of June 30, 2026, Sinotherapeutics, Inc. Class A has an Altman Z-Score of 14.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.